Sunil Gupta, MD
Internal Medicine · Cumberland, MDNPI 1093886657
Payments from drug & device makers
Across 117 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$293
- AstraZeneca$227
- Novo Nordisk$215
- Astellas Pharma US Inc$154
- Sanofi-aventis U.S. LLC$112
- Pfizer$78
- plus $542 from 15 others
What the payments were for
- Food & beverage$1,54695%
- Education$755%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 26 | $293 |
| AstraZeneca | 16 | $227 |
| Novo Nordisk | 18 | $215 |
| Astellas Pharma US Inc | 6 | $154 |
| Sanofi-aventis U.S. LLC | 9 | $112 |
| Pfizer | 5 | $78 |
| Lilly USA, LLC | 6 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| AbbVie | 4 | $64 |
| Novartis | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $43 |
| Amgen | 3 | $43 |
| Merck | 3 | $37 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Bayer | 1 | $23 |
| Abbott | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$1,621 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,400 | $613,124 |
| XareltoRivaroxaban | 254 | $113,812 |
| EntrestoSacubitril/Valsartan | 152 | $96,080 |
| FarxigaDapagliflozin Propanediol | 205 | $87,806 |
| OzempicSemaglutide | 68 | $74,068 |
| TrulicityDulaglutide | 83 | $70,933 |
| JardianceEmpagliflozin | 80 | $56,304 |
| JanuviaSitagliptin Phosphate | 59 | $47,187 |
| Tresiba Flextouch U-100Insulin Degludec | 112 | $43,887 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $43,074 |
| Dupixent SyringeDupilumab | 11 | $40,202 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $39,098 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 167 | $32,044 |
| Potassium Chloride | 1,101 | $30,742 |
| MyrbetriqMirabegron | 97 | $29,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $78 | $639,1461,482 claims |
| Johnson & JohnsonXarelto, Risperdal Consta, Invokana | $293 | $149,696308 claims |
| NovartisEntresto | $56 | $96,080152 claims |
| AstraZenecaFarxiga | $227 | $87,806205 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $77 | $87,26799 claims |
| Novo NordiskOzempic | $215 | $74,06868 claims |
| Boehringer IngelheimJardiance | $12 | $56,30480 claims |
| MerckJanuvia | $37 | $47,18759 claims |
| AbbVieRestasis, Linzess | $64 | $32,03250 claims |
| Astellas Pharma US IncMyrbetriq | $154 | $29,18497 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $27 | $21,95928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Cumberland
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.